Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flurbiprofen + gatifloxacin
- Development stage
- Unknown
- Lead developer
- Optho Pharma
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Flurgat is a fixed-dose combination ophthalmic solution containing the non-steroidal anti-inflammatory drug (NSAID) flurbiprofen and the fourth-generation fluoroquinolone antibiotic gatifloxacin. Developed by Optho Pharma, it is indicated for the treatment of bacterial eye infections (such as conjunctivitis) and the reduction of associated ocular inflammation, pain, and swelling. It is also used for pre- and post-operative prophylaxis and inflammation management in ophthalmic surgeries like cataract extraction. Flurbiprofen acts by inhibiting cyclooxygenase enzymes to reduce prostaglandin synthesis, thereby mitigating pain and inflammation, while gatifloxacin targets bacterial DNA gyrase and topoisomerase IV to inhibit bacterial replication.
- Brand names
- Flurgat
- Other names
- flurbiprofen and gatifloxacinflurbiprofen/gatifloxacingatifloxacin + flurbiprofengatifloxacin and flurbiprofengatifloxacin/flurbiprofen
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)TOP2 (DNA topoisomerase 2)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on flurbiprofen + gatifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flurbiprofen + gatifloxacin.